[go: up one dir, main page]

WO2006135436A3 - Inhibition of gene expression and therapeutic uses thereof - Google Patents

Inhibition of gene expression and therapeutic uses thereof Download PDF

Info

Publication number
WO2006135436A3
WO2006135436A3 PCT/US2005/037814 US2005037814W WO2006135436A3 WO 2006135436 A3 WO2006135436 A3 WO 2006135436A3 US 2005037814 W US2005037814 W US 2005037814W WO 2006135436 A3 WO2006135436 A3 WO 2006135436A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
expression
gene expression
sirnas
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/037814
Other languages
French (fr)
Other versions
WO2006135436A2 (en
Inventor
Alfred S Lewin
Sergei Zolotukhin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2006135436A2 publication Critical patent/WO2006135436A2/en
Anticipated expiration legal-status Critical
Publication of WO2006135436A3 publication Critical patent/WO2006135436A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RNA interference (RNAi) has become a powerful tool for blocking gene expression in mammals and mammalian cells. This approach requires the delivery of small interfering RNA (siRNA) either as RNA itself or as DNA, using an expression plasmid or virus and the coding sequence for small hairpin RNAs that are processed to siRNAs. Current expression systems for the production of siRNA in vivo rely on RNA polymerase III promoters. These are difficult to regulate and leave most of the RNA in the nucleus of the cell where it is inactive for RNA interference. The invention provides a DNA cassette for the cloning of small hairpin sequences which permit their expression and processing using RNA polymerase II. This system enables efficient transport of the pre-siRNAs to the cytoplasm where they are active and permits the use of regulated and tissue specific promoters for gene expression.
PCT/US2005/037814 2004-10-22 2005-10-21 Inhibition of gene expression and therapeutic uses thereof Ceased WO2006135436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62155404P 2004-10-22 2004-10-22
US60/621,554 2004-10-22

Publications (2)

Publication Number Publication Date
WO2006135436A2 WO2006135436A2 (en) 2006-12-21
WO2006135436A3 true WO2006135436A3 (en) 2009-06-04

Family

ID=37532749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/037814 Ceased WO2006135436A2 (en) 2004-10-22 2005-10-21 Inhibition of gene expression and therapeutic uses thereof

Country Status (1)

Country Link
WO (1) WO2006135436A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102851292B (en) * 2011-03-23 2014-04-02 中国农业科学院哈尔滨兽医研究所 siRNA sequences specifically silencing gI and gE gene of Marek's disease virus, and vector and preparation thereof

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906657A2 (en) 2008-01-29 2015-07-14 Proyecto Biomedicina Cima Sl Methods and compositions capable of synergistically causing post-transcriptional silencing of gene expression
EP2096174A1 (en) 2008-02-28 2009-09-02 Centro De Investigación Cooperativa En Biociencias CiC bioGune Ubiquitin binding polypeptides
BRPI0915093A2 (en) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugates for the administration of biologically active compounds
CN102325790A (en) 2008-12-03 2012-01-18 西马生物医学计划公司 Use of phenol-soluble modulins for vaccine development
EP2208785A1 (en) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
US20120237535A1 (en) 2009-09-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Therapeutic Compositions For The Treatment of HPV-Induced Diseases
CA2783876C (en) 2009-12-11 2018-04-03 Proyecto De Biomedicina Cima, S.L. New conjugates and compositions for immunotherapy and antitumoral treatment
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
WO2012001196A2 (en) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Alphaviral vectors and the uses thereof for heterologous gene expression
WO2012045894A1 (en) 2010-10-05 2012-04-12 Proyecto De Biomedicina Cima, S.L. Compounds and compositions for the treatment of illnesses caused by the hepatitis b virus
ES2562274T3 (en) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedure for the diagnosis, prognosis and treatment of breast cancer metastases
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
ES2525573T3 (en) 2011-05-24 2014-12-26 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High Affinity SUMO Traps
WO2013011153A2 (en) 2011-07-21 2013-01-24 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the prognosis and treatment of metastasis in breast cancer
ES2428405B1 (en) 2012-03-29 2014-06-02 Universidad De Valladolid Vehiculization of antigenic molecules in recombinant elastin-like polymers
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
KR20150021088A (en) 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 Vaccination with interleukin-4 antagonists
ES2705237T3 (en) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for diagnosis and prognosis of lung cancer metastasis
EP2687852A1 (en) 2012-07-17 2014-01-22 Laboratorios Del. Dr. Esteve, S.A. Method for diagnosing and treating chronic fatigue syndrome
DK2906718T3 (en) 2012-10-12 2019-07-01 Inbiomotion Sl PROCEDURE FOR DIAGNOSIS, PROGESTION AND TREATMENT OF PROSTATE STRENGTH METHODS USING C-MAF
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
BR112015023510A2 (en) 2013-03-15 2017-10-10 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for the diagnosis, prognosis and treatment of metastatic cancer
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
JP6550045B2 (en) 2013-10-09 2019-07-24 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） Methods for prognosis and treatment of breast cancer-derived bone metastasis cancer
CN117230193A (en) 2016-05-25 2023-12-15 生物运动有限公司 C-MAF state based therapeutic treatment of breast cancer
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
TWI605816B (en) * 2016-11-02 2017-11-21 國立屏東科技大學 Use of a dsrna against tyrosine hydroxylase
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US20200239529A1 (en) 2017-05-05 2020-07-30 Universitat Autònoma De Barcelona Nanostructured proteins and uses thereof
EP3427756A1 (en) 2017-07-14 2019-01-16 Universidad Autónoma De Barcelona (UAB) Therapeutic nanoconjugates and uses thereof
EP3713581A1 (en) 2017-11-22 2020-09-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
EP3626820A1 (en) 2018-09-20 2020-03-25 Fundación Imdea Nanociencia Anticancer compositions containing mirna mimics and uses thereof
KR20220012839A (en) 2019-03-19 2022-02-04 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 Combination therapy for cancer treatment using OMOMYC and antibodies that bind to PD-1 or CTLA-4
WO2021034275A1 (en) * 2019-08-22 2021-02-25 National University Of Singapore Method for the generation of dumbbell-shaped dna vectors
US20230265422A1 (en) * 2019-10-15 2023-08-24 The Scripps Research Institute Efficient rna switches and related expression systems
EP3974440A1 (en) 2020-09-23 2022-03-30 Universite Paul Sabatier Toulouse Iii High affinity binders of proteins of the atg8 family
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment
KR20250089547A (en) 2022-10-25 2025-06-18 펩토믹, 에스.엘. Combination therapy for cancer treatment
EP4619417A1 (en) 2022-11-15 2025-09-24 Universitat Autònoma de Barcelona Nanoconjugates containing pdgfr-beta ligands and uses thereof
CN118109460B (en) * 2022-12-28 2024-11-19 恺佧生物科技(上海)有限公司 IVT reaction by-product formation mechanism and design application of repression module
EP4410825A1 (en) 2023-02-03 2024-08-07 Servizo Galego de Saude Fragments of the n-terminal domain of gsdmb for the treatment of cancer
EP4446742A1 (en) 2023-04-14 2024-10-16 Peptomyc, S.L. Method for assessing or monitoring the response to a cancer treatment
TW202513088A (en) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 Combination therapy with mek inhibitors for the treatment of cancer
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
EP4616864A1 (en) 2024-03-11 2025-09-17 Peptomyc, S.L. Compound for the treatment of autoimmune diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157691A1 (en) * 2001-09-13 2003-08-21 Xiao-Feng Qin Method for expression of small antiviral RNA molecules within a cell
US20030180756A1 (en) * 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
US20040219671A1 (en) * 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157691A1 (en) * 2001-09-13 2003-08-21 Xiao-Feng Qin Method for expression of small antiviral RNA molecules within a cell
US20040219671A1 (en) * 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20030180756A1 (en) * 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102851292B (en) * 2011-03-23 2014-04-02 中国农业科学院哈尔滨兽医研究所 siRNA sequences specifically silencing gI and gE gene of Marek's disease virus, and vector and preparation thereof

Also Published As

Publication number Publication date
WO2006135436A2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
WO2006135436A3 (en) Inhibition of gene expression and therapeutic uses thereof
Triboulet et al. Post-transcriptional control of DGCR8 expression by the Microprocessor
EP2585595B1 (en) Rna molecules and uses thereof
EP2925866B1 (en) Circular rna for inhibition of microrna
Kennedy et al. Production of functional small interfering RNAs by an amino-terminal deletion mutant of human Dicer
Jensen et al. Comparison of small interfering RNA (siRNA) delivery into bovine monocyte-derived macrophages by transfection and electroporation
WO2008156702A3 (en) Bacteria mediated gene silencing
EP4455285A3 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
You et al. HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy
WO2021252924A8 (en) Arrdc1-mediated microvesicle-based delivery to the nervous system
Kizana et al. Non-cell-autonomous effects of vector-expressed regulatory RNAs in mammalian heart cells
Jadhav et al. Antagomirzymes: oligonucleotide enzymes that specifically silence microRNA function
WO2019140116A3 (en) Amplifiable rnas for therapeutic cell systems
AU2019382824A8 (en) Method and means to deliver miRNA to target cells
Herrera-Carrillo et al. Influence of the loop size and nucleotide composition on AgoshRNA biogenesis and activity
Kudo et al. Usage of putative chicken U6 promoters for vector-based RNA interference
Younger et al. Transcriptional regulation by miRNA mimics that target sequences downstream of gene termini
GB201103167D0 (en) Gene silencing
Gvozdeva et al. 42-and 63-bp anti-MDR1-siRNAs bearing 2′-OMe modifications in nuclease-sensitive sites induce specific and potent gene silencing
Zenke et al. Novel fugu U6 promoter driven shRNA expression vector for efficient vector based RNAi in fish cell lines
ATE428783T1 (en) EXPRESSION SYSTEM FOR SIRNA
Peng et al. shRNA driven by Pol II/T7 dual-promoter system effectively induce cell-specific RNA interference in mammalian cells
EP2955228B1 (en) Small interference rna for inhibiting intracellular expression of ribosomal protein s3
CN105200056B (en) A kind of method and application that mitochondrial gene expression is adjusted using tiny RNA
de Mello et al. Modulating gene expression as a strategy to investigate thyroid cancer biology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05857964

Country of ref document: EP

Kind code of ref document: A2